EMADOC-1700519818-1802285

European Medicines Agency decision

EMA/PE/0000224955

of 3 January 2025

on the acceptance of a modification of an agreed paediatric investigation plan for ribitol in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA/PE/0000224955

of 3 January 2025

on the acceptance of a modification of an agreed paediatric investigation plan for ribitol in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0387/2021 issued on 8 September 2021,

Having regard to the application submitted by BridgeBio Europe B.V. on 6 August 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 November 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ribitol, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to BridgeBio Europe B.V., Weerdestein 97, 1083 GG – Amsterdam, Netherlands.

EMADOC-1700519818-1673943
Amsterdam, 15 November 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA/PE/0000224955

Scope of the application

Active substance(s):

Ribitol

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of limb-girdle muscular dystrophy

Pharmaceutical form(s):

Powder for oral use

Age-appropriate oral dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

BridgeBio Europe B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, BridgeBio Europe B.V. submitted to the European Medicines Agency on 6 August 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0387/2021 issued on 8 September 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 16 September 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of limb-girdle muscular dystrophy

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients from birth to less than 18 years of age with a genetically confirmed diagnosis of Limb-Girdle muscular dystrophy (LGMD) type 2i/ LGMD R9-fukutin related or subtypes LGMD2M and LGMD2U

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for oral use

Age-appropriate oral dosage form

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age-appropriate oral dosage form (powder for oral use) suitable for children younger than 12 years of age including age-appropriate excipients and age-appropriate flavourings
Non-clinical studies	**Study 2** Definitive juvenile toxicity study in rats
Clinical studies	**Study 3** Open label, single arm study to assess the safety, tolerability and pharmacokinetics of ascending doses of ribitol in paediatric patients from 12 years to less than 18 years of age (and adults) with Limb Girdle muscular dystrophy (LGMD) 2I (MLB-01-003) **Study 4** Double blind, placebo controlled study to assess pharmacokinetics, safety and efficacy of ribitol compared to placebo in paediatric patients from 12 years to less than 18 years of age (and adults) with Limb Girdle muscular dystrophy (LGMD) 2I (MLB-01-005)

	Study 5 Open label, single arm study to assess the safety, tolerability, pharmacokinetics and clinical activity of ribitol in paediatric patients from birth to less than 18 years of age (and adults) with Limb Girdle muscular dystrophy type 2M and 2U (MLB-01-XXX) **Study 6** Observational study aimed at collecting data on clinical outcome assessments in paediatric patients from 10 years to less than 18 years of age (and adults) with Limb Girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). (MLB-01-001) **Study 9** *added in procedure EMA/PE/0000224955 (15 Nov 2024)* Open label, single arm trial to evaluate the safety, pharmacokinetics and pharmacodynamics and selected clinical activity of ribitol in paediatric patients from birth to less than 12 years of age with genetically confirmed limb girdle muscular dystrophy 2I/R9.
Extrapolation, modelling and simulation studies	**Study 7** Modelling and simulation study to further determine the dose of ribitol to be used in paediatric patients from birth to less than 18 years of age with Limb Girdle muscular dystrophy type 2 **Study 8** Exposure-Response (E-R) model to describe the relationship between ribitol and ADG glycosylation in paediatric patients from birth to less than 18 years of age with Limb Girdle muscular dystrophy type 2
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2031
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.